Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Research & Development (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Research & Development for 4 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 12.7% to $7.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.8 million, a 3.82% decrease, with the full-year FY2025 number at $32.8 million, down 3.82% from a year prior.
  • Research & Development was $7.5 million for Q4 2025 at Phathom Pharmaceuticals, up from $7.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $19.0 million in Q3 2022 to a low of $7.0 million in Q3 2025.
  • A 4-year average of $11.8 million and a median of $10.5 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 42.21% in 2024, then grew 23.05% in 2025.
  • Phathom Pharmaceuticals' Research & Development stood at $15.9 million in 2022, then dropped by 16.0% to $13.4 million in 2023, then crashed by 35.92% to $8.6 million in 2024, then fell by 12.7% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Research & Development are $7.5 million (Q4 2025), $7.0 million (Q3 2025), and $9.1 million (Q2 2025).